var data={"title":"Darbepoetin alfa: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Darbepoetin alfa: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5980?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=darbepoetin-alfa-patient-drug-information\" class=\"drug drug_patient\">see &quot;Darbepoetin alfa: Patient drug information&quot;</a> and <a href=\"topic.htm?path=darbepoetin-alfa-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Darbepoetin alfa: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50080059\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Aranesp Canadian Safety Alert</span>\n      <span class=\"collapsible-date\">May 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has announced that severe and life-threatening skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in patients treated with darbepoetin alfa (Aranesp). Health care providers are advised to discontinue darbepoetin alfa immediately if a severe skin reaction occurs or SJS/TEN is suspected and to permanently discontinue darbepoetin alfa if SJS/TEN is confirmed. Health Canada is currently working with the manufacturer to include this safety information in the Canadian Product Monograph.</p>\n        <p style=\"text-indent:0em;\">For further information visit http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/63198a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708695\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiovascular events:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Erythropoiesis-stimulating agents (ESAs) increase the risk of death, myocardial infarction (MI), stroke, venous thromboembolism, thrombosis of vascular access.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Chronic kidney disease:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered ESAs to target a hemoglobin level of more than 11 g/dL.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">No trial has identified a hemoglobin target level, darbepoetin alfa dose, or dosing strategy that does not increase these risks.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use the lowest darbepoetin alfa dose sufficient to reduce the need for red blood cell (RBC) transfusions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cancer:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusion.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use ESAs only for treatment of anemia from myelosuppressive chemotherapy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Discontinue following the completion of a chemotherapy course.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156983\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aranesp (Albumin Free)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156984\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Aranesp</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157010\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Colony Stimulating Factor;</li>\n      <li>\n        Erythropoiesis-Stimulating Agent (ESA);</li>\n      <li>\n        Hematopoietic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156985\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Evaluate iron status in all patients before and during treatment. The manufacturer recommends supplemental iron be administered if serum ferritin is &lt;100 ng/mL or serum transferrin saturation (TSAT) is &lt;20%. Most patients with CKD will require iron supplementation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anemia due to chronic kidney disease (CKD):</b> Individualize dosing and use the lowest dose necessary to reduce the need for red blood cell (RBC) transfusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic kidney disease patients </i> <b><i>ON dialysis</i></b> (IV route is preferred for hemodialysis patients; initiate treatment when hemoglobin is &lt;10 g/dL; reduce dose or interrupt treatment if hemoglobin approaches or exceeds 11 g/dL): IV, SubQ: Initial: 0.45 mcg/kg once weekly <b>or</b> 0.75 mcg/kg once every 2 weeks <b>or</b> conversion from epoetin alfa: Epoetin alfa doses of &lt;1,500 to &ge;90,000 units per week may be converted to darbepoetin alfa doses ranging from 6.25 to 200 mcg per week (see adult column in conversion table below).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic kidney disease patients </i> <b><i>NOT on dialysis </i></b> (consider initiating treatment when hemoglobin is &lt;10 g/dL; use only if rate of hemoglobin decline would likely result in RBC transfusion and desire is to reduce risk of alloimmunization or other RBC transfusion-related risks; reduce dose or interrupt treatment if hemoglobin exceeds 10 g/dL): IV, SubQ: Initial: 0.45 mcg/kg once every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosage adjustments for chronic kidney disease patients (either on dialysis or not on dialysis):</i> Do not increase dose more frequently than every 4 weeks (dose decreases may occur more frequently).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin increases &gt;1 g/dL in any 2-week period: Decrease dose by &ge;25%.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin does not increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inadequate or lack of response: If adequate response is not achieved over 12 weeks, further increases are unlikely to be of benefit and may increase the risk for adverse events; use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid RBC transfusions <b>and</b> evaluate patient for other causes of anemia; discontinue treatment if responsiveness does not improve</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Anemia due to chemotherapy in cancer patients:</b> Initiate treatment only if hemoglobin &lt;10 g/dL and anticipated duration of myelosuppressive chemotherapy is at least 2 additional months. Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid RBC transfusions. Discontinue darbepoetin alfa following completion of chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: Initial: 2.25 mcg/kg once weekly <b>or</b> 500 mcg once every 3 weeks until completion of a chemotherapy course</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosage adjustments:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Increase dose: If hemoglobin does not increase by 1 g/dL <b>and</b> remains below 10 g/dL after initial 6 weeks (for patients receiving weekly therapy only), increase dose to 4.5 mcg/kg once weekly (no dosage adjustment if using every-3-week dosing).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Reduce dose by 40% if hemoglobin increases &gt;1 g/dL in any 2-week period <b>or</b> hemoglobin reaches a level sufficient to avoid RBC transfusion.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Withhold dose if hemoglobin exceeds a level needed to avoid RBC transfusion. Resume treatment with a 40% dose reduction when hemoglobin approaches a level where transfusions may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Discontinue: On completion of chemotherapy or if after 8 weeks of therapy there is no hemoglobin response or RBC transfusions still required</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Symptomatic anemia in myelodysplastic syndromes  (off-label use):</b> SubQ: 150 to 300 mcg once weekly (Giraldo 2006; Stasi 2005) <b>or</b> 500 mcg once every 2 to 3 weeks (Gabrilove 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Conversion from epoetin alfa to darbepoetin alfa in CKD (on dialysis): See table</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Conversion From Epoetin Alfa to Darbepoetin Alfa in Chronic Kidney Disease (Estimated Initial Dose)</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;text-align:center;\">Previous Dosage of Epoetin Alfa</p>\n            <p style=\"text-indent:0em;text-align:center;\">(units/week)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;text-align:center;\">Children</p>\n            <p style=\"text-indent:0em;text-align:center;\">Darbepoetin Alfa Dosage</p>\n            <p style=\"text-indent:0em;text-align:center;\">(mcg/week)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;text-align:center;\">Adults</p>\n            <p style=\"text-indent:0em;text-align:center;\">Darbepoetin Alfa Dosage</p>\n            <p style=\"text-indent:0em;text-align:center;\">(mcg/week)</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Note:</b> In patients receiving epoetin alfa 2 to 3 times per week, darbepoetin alfa is administered once weekly. In patients receiving epoetin alfa once weekly, darbepoetin alfa is administered once every 2 weeks. The darbepoetin alfa dose to be administered every 2 weeks is derived by adding together 2 weekly epoetin alfa doses and then converting to the appropriate darbepoetin alfa dose. Titrate dose to hemoglobin response thereafter. The dose conversion in this table does not accurately estimate the once-monthly dose in chronic kidney disease (CKD) patients not on dialysis.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;1,500</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Not established</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6.25</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,500 to 2,499</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6.25</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6.25</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2,500 to 4,999</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12.5</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5,000 to 10,999</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">11,000 to 17,999</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">18,000 to 33,999</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">34,000 to 89,999</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;90,000</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5026026\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=darbepoetin-alfa-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Darbepoetin alfa: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Evaluate iron status in all patients before and during treatment. The manufacturer recommends supplemental iron be administered if serum ferritin is &lt;100 ng/mL or serum transferrin saturation (TSAT) is &lt;20%. Most patients with CKD will require iron supplementation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anemia due to chronic kidney disease (CKD):</b> Individualize dosing and use the lowest dose necessary to reduce the need for red blood cell (RBC) transfusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic kidney disease patients </i> <b><i>ON dialysis</i></b> (IV route is preferred for hemodialysis patients; initiate treatment when hemoglobin is &lt;10 g/dL; reduce dose or interrupt treatment if hemoglobin approaches or exceeds 12 g/dL): IV, SubQ: Initial: 0.45 mcg/kg once weekly or conversion from epoetin alfa: Initial dose: Epoetin alfa doses of 1,500 to &ge;90,000 units per week may be converted to darbepoetin alfa doses ranging from 6.25 to 200 mcg per week (see conversion table in adult dosing).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic kidney disease patients</i> <b>NOT on dialysis</b> (consider initiating treatment when hemoglobin is &lt;10 g/dL; use only if rate of hemoglobin decline would likely result in RBC transfusion and desire is to reduce risk of alloimmunization or other RBC transfusion-related risks; reduce dose or interrupt treatment if hemoglobin exceeds 12 g/dL): IV, SubQ: Initial: 0.45 mcg/kg once weekly or 0.75 mcg/kg once every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosage adjustments for chronic kidney disease patients:</i> Do not increase dose more frequently than every 4 weeks (dose decreases may occur more frequently).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin increases &gt;1 g/dL in any 2-week period: Decrease dose by &ge;25%.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin does not increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inadequate or lack of response: If adequate response is not achieved over 12 weeks, further increases are unlikely to be of benefit and may increase the risk for adverse events; use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid RBC transfusions <b>and</b> evaluate patient for other causes of anemia; discontinue treatment if responsiveness does not improve.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156986\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15795977\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15795978\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156961\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aranesp (Albumin Free): 25 mcg/mL (1 mL); 40 mcg/mL (1 mL); 60 mcg/mL (1 mL); 100 mcg/mL (1 mL); 150 mcg/0.75 mL (0.75 mL [DSC]); 200 mcg/mL (1 mL); 300 mcg/mL (1 mL) [albumin free; contains mouse (murine) and/or hamster protein, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aranesp (Albumin Free): 10 mcg/0.4 mL (0.4 mL); 25 mcg/0.42 mL (0.42 mL); 40 mcg/0.4 mL (0.4 mL); 60 mcg/0.3 mL (0.3 mL); 100 mcg/0.5 mL (0.5 mL); 150 mcg/0.3 mL (0.3 mL); 200 mcg/0.4 mL (0.4 mL); 300 mcg/0.6 mL (0.6 mL); 500 mcg/mL (1 mL) [albumin free; contains mouse (murine) and/or hamster protein, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156947\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874543\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103951s5375lbl.pdf#page=25&amp;token=vGWlCfEYW79EZLSeG8kYJH9emtrpASSVXWLbMiNXfo79r0J0U2n6A065FPtnfhoz4rmC2rRPTEdlc+muEMobILp69bgIa57F8XwDf5nZXnXwtTMLPNb/fGuF92ocNSr0&amp;TOPIC_ID=8662\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103951s5375lbl.pdf#page=25</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156963\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV, SubQ: May be administered by SubQ or IV injection. The IV route is recommended in hemodialysis patients. Do not shake; vigorous shaking may denature darbepoetin alfa, rendering it biologically inactive. Do not dilute or administer in conjunction with other drug solutions. Discard any unused portion of the vial; do not pool unused portions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156962\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anemia due to chemotherapy in patients with cancer:</b> Treatment of anemia in patients with nonmyeloid malignancies when anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of 2 additional months of planned chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anemia due to chronic kidney disease: </b>Treatment of anemia due to chronic kidney disease, including patients on dialysis and patients not on dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Darbepoetin alfa has not demonstrated improved quality of life, fatigue, or well-being. Darbepoetin alfa is <b>not </b>indicated for use under the following conditions:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Cancer patients receiving hormonal therapy, therapeutic biologic products, or radiation therapy unless also receiving concurrent myelosuppressive chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Cancer patients receiving myelosuppressive chemotherapy when the expected outcome is curative</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Cancer patients receiving myelosuppressive chemotherapy when anemia can be managed by transfusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- As a substitute for red blood cell (RBC) transfusion in patients requiring immediate correction of anemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725530\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Symptomatic anemia in myelodysplastic syndromes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2136826\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aranesp may be confused with Aralast, Aricept</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Darbepoetin alfa may be confused with dalteparin, epoetin alfa, methoxy polyethylene glycol-epoetin beta</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156953\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (31%), peripheral edema (17%), edema (6% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (10% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (17%), cough (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Angina pectoris, hypotension, myocardial infarction, pulmonary embolism, thromboembolism, thrombosis of hemodialysis vascular access, thrombosis of vascular graft (arteriovenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Cerebrovascular disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypervolemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, anemia (associated with neutralizing antibodies; severe; with or without other cytopenias), angioedema, bronchospasm, cerebrovascular accident, hypersensitivity reaction, hypertensive encephalopathy, pure red cell aplasia, seizure, tumor growth (progression/recurrence; cancer patients), urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156966\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serious allergic reaction to darbepoetin alfa or any component of the formulation; uncontrolled hypertension; pure red cell aplasia (PRCA) that begins after treatment with darbepoetin alfa or other erythropoietin protein drugs</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Sensitivity to mammalian cell-derived products</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156951\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: <b>[US Boxed Warning]: Erythropoiesis-stimulating agents (ESAs) increased the risk of serious cardiovascular events, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and mortality in clinical studies when administered to target hemoglobin levels &gt;11 g/dL</b> (and provide no additional benefit); a rapid rise in hemoglobin (&gt;1 g/dL over 2 weeks) may also contribute to these risks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous reactions: Erythema multiforme and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) have been reported with ESA use; discontinue immediately if a severe cutaneous reaction develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Potentially serious allergic reactions have been reported (rarely), including anaphylactic reactions, angioedema, bronchospasm, rash, and urticaria. Discontinue immediately (and permanently) in patients who experience serious allergic/anaphylactic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pure red cell aplasia (PRCA): Cases of severe anemia and PRCA (with or without other cytopenias) have been reported, predominantly in patients with chronic kidney disease receiving SubQ darbepoetin alfa (the intravenous [IV] route is preferred for hemodialysis patients). Cases have also been reported in patients with hepatitis C who were receiving ESAs, interferon, and ribavirin. Patients with a sudden loss of response to darbepoetin alfa (with severe anemia and a low reticulocyte count) should be evaluated for PRCA with associated neutralizing antibodies to erythropoietin; discontinue treatment (permanently) in patients with PRCA secondary to neutralizing antibodies to erythropoietin. Antibodies may cross-react; do not switch to another ESA in patients who develop antibody-mediated anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cancer patients: <b>[US Boxed Warning]: A shortened overall survival and/or increased risk of time to tumor progression or recurrence has been reported in studies with breast, cervical, head and neck, lymphoid, and non-small cell lung cancer patients.</b> It is of note that in most of these studies, patients received ESAs to a target hemoglobin of &ge;12 g/dL; although risk has not been excluded when dosed to achieve a target hemoglobin of &lt;12 g/dL. <b>[US Boxed Warnings]: To decrease these risks, and risk of cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusions. Use ESAs in cancer patients only for the treatment of anemia related to concurrent myelosuppressive chemotherapy; discontinue ESA following completion of the chemotherapy course. ESAs are <span style=\"text-decoration: underline\">not</span> indicated for patients receiving myelosuppressive therapy when the anticipated outcome is curative.</b> A dosage modification is appropriate if hemoglobin levels rise &gt;1 g/dL per 2-week time period during treatment (Rizzo 2010). Use of ESAs has been associated with an increased risk of venous thromboembolism (VTE) without a reduction in transfusions in patients &gt;65 years of age with cancer (Hershman 2009). Improved anemia symptoms, quality of life, fatigue, or well-being have not been demonstrated in controlled clinical trials.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic kidney disease patients: <b>[US Boxed Warning]: An increased risk of death, serious cardiovascular events, and stroke was reported in chronic kidney disease patients administered ESAs to target hemoglobin levels &gt;11 g/dL; use the lowest dose sufficient to reduce the need for RBC transfusions. An optimal target hemoglobin level, dose, or dosing strategy to reduce these risks has not been identified in clinical trials. </b> Hemoglobin rising &gt;1 g/dL in a 2-week period may contribute to the risk (dosage reduction recommended). Chronic kidney disease patients who exhibit an inadequate hemoglobin response to ESA therapy may be at a higher risk for cardiovascular events and mortality compared to other patients. ESA therapy may reduce dialysis efficacy (due to increase in red blood cells and decrease in plasma volume); adjustments in dialysis parameters may be needed. Chronic kidney disease patients not requiring dialysis may have a better response to darbepoetin alfa and may require lower doses. Patients treated with ESAs may require increased heparinization during dialysis to prevent clotting of the extracorporeal circuit.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Use with caution in patients with a history of hypertension; use is contraindicated in patients with uncontrolled hypertension. An excessive rate of rise of hemoglobin may be associated with exacerbation of hypertension; decrease the darbepoetin alfa dose if the hemoglobin increase exceeds 1 g/dL in any 2-week period. Blood pressure should be controlled prior to start of therapy and monitored closely throughout treatment. Hypertensive encephalopathy has been reported with patients receiving erythropoietic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Perisurgical patients: Increased mortality was observed in patients undergoing coronary artery bypass surgery who received epoetin; these deaths were associated with thrombotic events. An increased risk of deep vein thrombosis has been observed in patients treated with epoetin undergoing surgical orthopedic procedures. Darbepoetin alfa is <b>not</b> approved for reduction in allogeneic red blood cell transfusions in patients scheduled for surgical procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: The risk for seizures is increased with darbepoetin alfa use in patients with chronic kidney disease; use with caution in patients with a history of seizures. Monitor closely for neurologic symptoms during the first several months of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Severe anemia or acute blood loss: Due to the delayed onset of erythropoiesis, darbepoetin alfa is not recommended for acute correction of severe anemia or as a substitute for emergency transfusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: The packaging of some formulations may contain latex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Oncology: The American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) 2010 updates to the clinical practice guidelines for the use of ESAs in patients with cancer indicate that ESAs are appropriate when used according to the parameters identified within the FDA-approved labeling for epoetin and darbepoetin alfa (Rizzo 2010). ESAs are an option for chemotherapy-associated anemia when the hemoglobin has fallen to &lt;10 g/dL to decrease the need for red blood cell transfusions. ESAs should only be used in conjunction with concurrent chemotherapy. Although the FDA label now limits ESA use to the palliative setting, the ASCO/ASH guidelines suggest using clinical judgment in weighing risks versus benefits as formal outcomes studies of ESA use defined by intent of chemotherapy treatment have not been conducted.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Cardiovascular disease: The American College of Physicians recommends against the use of ESAs in patients with mild to moderate anemia and heart failure or coronary heart disease (ACP [Qaseem 2013]). The American College of Cardiology Foundation/American Heart Association (ACCF/AHA) 2013 Heart Failure Guidelines do not provide a clear recommendation on the use of ESAs in anemic heart failure patients. The effects of ESAs on quality of life measures, morbidity, and mortality are potentially modest and still unclear. The authors declined to provide an official recommendation regarding the use of ESAs pending the completion of ongoing randomized trials (ACCF/AHA [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Factors impairing erythropoiesis: Prior to treatment, correct or exclude deficiencies of iron, vitamin B<sub>12</sub>, and/or folate, as well as other factors that may impair erythropoiesis (inflammatory conditions, infections, bleeding). Poor response to therapy should prompt evaluation of potential factors impairing erythropoiesis, as well as possible malignant processes and hematologic disease (thalassemia, refractory anemia, myelodysplastic disorder), occult blood loss, hemolysis, osteitis fibrosa cystic, and/or bone marrow fibrosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299127\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156955\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8662&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Lenalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nandrolone: May enhance the stimulatory effect of Erythropoiesis-Stimulating Agents. Specifically, nandrolone may enhance the erythropoiesis stimulatory effect of Erythropoiesis-Stimulating Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Pomalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156957\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156969\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Women who become pregnant during treatment with darbepoetin alfa are encouraged to enroll in Amgen&rsquo;s Pregnancy Surveillance Program (800-772-6436).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20305960\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if darbepoetin alfa is present in breast milk. The manufacturer recommends that caution be exercised when administering darbepoetin alfa to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156970\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Supplemental iron intake may be required in patients with low iron stores.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156959\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hemoglobin (at least once per week until maintenance dose established and after dosage changes; monitor less frequently once hemoglobin is stabilized); CKD patients should be also be monitored at least monthly following hemoglobin stability); iron stores (transferrin saturation and ferritin) prior to and during therapy; serum chemistry (CKD patients); blood pressure; fluid balance (CKD patients); monitor for signs of seizures (CKD patients following initiation for first few months, includes new-onset or change in seizure frequency or premonitory symptoms)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Cancer patients: Examinations recommended by the ASCO/ASH guidelines (Rizzo 2010) prior to treatment include peripheral blood smear (in some situations a bone marrow exam may be necessary), assessment for iron, folate, or vitamin B<sub>12</sub> deficiency, reticulocyte count, renal function status, and occult blood loss; during ESA treatment, assess baseline and periodic iron, total iron-binding capacity, and transferrin saturation or ferritin levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156950\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Darbepoetin alfa induces erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells; induces the release of reticulocytes from the bone marrow into the bloodstream, where they mature to erythrocytes. There is a dose-response relationship with this effect. This results in an increase in reticulocyte counts followed by a rise in hematocrit and hemoglobin levels. When administered SubQ or IV, darbepoetin alfa's half-life is ~3 times that of epoetin alfa concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156965\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Increased hemoglobin levels not generally observed until 2 to 6 weeks after initiating treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: SubQ: Slow</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: Initial dose: 51.6 &plusmn; 13.7 mL/kg; Steady state: 80.9 &plusmn; 32.5 mL/kg (Lerner 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 52.4 &plusmn; 2 mL/kg (Macdougall 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: CKD: SubQ: Adults: ~37% (range: 30% to 50%); Children: 54% (range: 32% to 70%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: <b>Note:</b> Darbepoetin alfa half-life is approximately 3-fold longer than epoetin alfa following IV administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents (Lerner 2002):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Terminal: 22.1 &plusmn; 4.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">SubQ: Terminal: 42.8 &plusmn; 23 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 21 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">SubQ: Nondialysis patients: 70 hours (range: 35 to 139 hours), Dialysis patients: 46 hours (range: 12 to 89 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cancer:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: SubQ: 49.4 &plusmn; 32 hours (Blumer 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: SubQ: 74 hours (range: 24 to 144 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: 36.2 &plusmn; 14.1 hours (Lerner 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 48 hours (range: 12 to 72 hours; independent of dialysis)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cancer:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: 87.5 &plusmn; 53 hours (Blumer 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 71 hours (range: 28 to 123 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156968\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aranesp (Albumin Free) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg/mL (1 mL): $232.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mcg/mL (1 mL): $371.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mcg/mL (1 mL): $557.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/mL (1 mL): $928.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/mL (1 mL): $1,857.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg/mL (1 mL): $2,786.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Aranesp (Albumin Free) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg/0.4 mL (0.4 mL): $92.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg/0.42 mL (0.42 mL): $232.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mcg/0.4 mL (0.4 mL): $371.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mcg/0.3 ml (0.3 mL): $557.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/0.5 mL (0.5 mL): $928.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mcg/0.3 ml (0.3 mL): $1,393.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/0.4 mL (0.4 mL): $1,857.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg/0.6 mL (0.6 mL): $2,786.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg/mL (1 mL): $4,644.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038595\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actorise (IN);</li>\n      <li>Aranesp (AE, AT, AU, BB, BE, BG, BH, CH, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HN, HR, IE, IL, IS, IT, JO, KW, LB, LT, LU, LV, MT, NI, NL, NO, NZ, PA, PL, PT, QA, RO, SA, SE, SI, SK, SV, TR, TW, UA);</li>\n      <li>NESP (HK, JP, KR, MY, PH, SG, TH, TW);</li>\n      <li>Nespo (SE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andre JL, Deschenes G, Boudaillies B, et al, &ldquo;Darbepoetin, Effective Treatment of Anaemia in Paediatric Patients With Chronic Renal Failure,&rdquo; <i>Pediatr Nephrol</i>, 2007, 22(5):708-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/17216497/pubmed\" target=\"_blank\" id=\"17216497\">17216497</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aranesp (darbepoetin alfa) [prescribing information]. Thousand Oaks, CA: Amgen Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aranesp (darbepoetin alfa) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bennett CL, Silver SM, Djulbegovic B, et al, &ldquo;Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia,&rdquo; <i>JAMA</i>, 2008, 299(8):914-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/18314434/pubmed\" target=\"_blank\" id=\"18314434\">18314434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Besarab A, Bolton WK, Browne JK, et al, &ldquo;The Effects of Normal as Compared With Low Hematocrit Values in Patients With Cardiac Disease Who Are Receiving Hemodialysis and Epoetin,&rdquo; <i>N Engl J Med</i>, 1998, 339(9):584-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/9718377/pubmed\" target=\"_blank\" id=\"9718377\">9718377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17120240\"></a>Blumer J, Berg S, Adamson PC, Loew T, Rossi G, Hastings C. Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia.<i> Pediatr Blood Cancer</i>. 2007;49(5):687-693.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/17120240/pubmed\" target=\"_blank\" id=\"17120240\">17120240</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bristoyiannis G, Germanos N, Grekas D, et al, &ldquo;Unit Dosing of Darbepoetin Alfa for the Treatment of Anemia in Patients With End-Stage Renal Disease Being Switched From Recombinant Human Erythropoietin: Results of a Phase IIIb, 27-Week, Multicenter, Open-Label Study in Greek Patients,&rdquo; <i>Curr Ther Res</i>, 2005, 66(3):195-211.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canon JL, Vansteenkiste J, Bodoky G, et al, &ldquo;Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia,&rdquo; <i>J Natl Cancer Inst</i>, 2006, 98(4):273-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/16478746/pubmed\" target=\"_blank\" id=\"16478746\">16478746</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L , Berkovits E, Goldman WM. Room-temperature storage of medications labeled for refrigeration [published correction appears in <i>Am J Health Syst Pharm</i>. 2007;64(21):2218]. <i>Am J Health-Syst Pharm</i>. 2007;64(16):1711-1715.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corwin HL, Gettinger A, Fabian TC, et al, &quot;Efficacy and Safety of Epoetin Alfa in Critically Ill Patients,&quot; <i>N Engl J Med</i>, 2007, 357(10):965-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/17804841/pubmed\" target=\"_blank\" id=\"17804841\">17804841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corwin HL, Gettinger A, Pearl RG, et al, &ldquo;Efficacy of Recombinant Human Erythropoietin in Critically Ill Patients: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2002, 288(22):2827-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/12472324/pubmed\" target=\"_blank\" id=\"12472324\">12472324</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drueke TB, Locatelli F, Clyne N, et al, &ldquo;Normalization of Hemoglobin Level in Patients With Chronic Kidney Disease and Anemia,&rdquo; <i>N Engl J Med</i>, 2006, 355(20): 2071-84.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Egrie JC and Browne KJ, &ldquo;Development and Characterization of Novel Erythropoiesis Stimulation Protein (NESP),&rdquo; <i>Br J Cancer</i>, 2001, 84(Suppl 1):3-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/11308268/pubmed\" target=\"_blank\" id=\"11308268\">11308268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fenaux P, Haase D, Sanz GF, Santini V, Buske C; ESMO Guidelines Working Group. Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2014;25(suppl 3):iii57-iii69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/25185242/pubmed\" target=\"_blank\" id=\"25185242\">25185242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18540943\"></a>Gabrilove J, Paquette R, Lyons RM, et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. <i>Br J Haematol</i>. 2008;142(3):379-393.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/18540943/pubmed\" target=\"_blank\" id=\"18540943\">18540943</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17115424\"></a>Giraldo P, Nomdedeu B, Loscertales J, et al; Aranesp in Myelodysplastic Syndromes (ARM) Study Group. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. <i>Cancer</i>. 2006;107(12):2807-2816.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/17115424/pubmed\" target=\"_blank\" id=\"17115424\">17115424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hebert PC, Wells G, Blajchman MA, et al, &ldquo;A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group,&rdquo; <i>N Engl J Med</i>, 1999, 340(6):409-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/9971864/pubmed\" target=\"_blank\" id=\"9971864\">9971864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hershman DL, Buono DL, Malin J, et al, &ldquo;Patterns of Use and Risks Associated With Erythropoiesis-Stimulating Agents Among Medicare Patients With Cancer,&rdquo; <i>J Natl Cancer Inst</i>, 2009, 101(23):1-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/19903808/pubmed\" target=\"_blank\" id=\"19903808\">19903808</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Arena F, Patel D, et al, &ldquo;A Randomized Controlled Trial of Darbepoetin Alfa Administered as a Fixed or Weight-Based Dose Using a Front-Loading Schedule in Patients With Anemia Who Have Nonmyeloid Malignancies,&rdquo; <i>Cancer</i>, 2004, 100(4):859-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/14770445/pubmed\" target=\"_blank\" id=\"14770445\">14770445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jadoul M, Vanrenterghem Y, Foret M, et al, &ldquo;Darbepoetin Alfa Administered Once Monthly Maintains Haemoglobin Levels in Stable Dialysis Patients,&rdquo; <i>Nephrol Dial Transplant</i>, 2004, 19(4):898-903.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/15031347/pubmed\" target=\"_blank\" id=\"15031347\">15031347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lerner G, Kale AS, Warady BA, et al. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol. 2002;17(11):933-937.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/12432437/pubmed\" target=\"_blank\" id=\"12432437\">12432437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. <i>J Am Soc Nephrol.</i> 1999;10(11):2392-2395.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/10541299/pubmed\" target=\"_blank\" id=\"10541299\">10541299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malcovati L, Hellstr&ouml;m-Lindberg E, Bowen D, et al; European Leukemia Net. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. <i>Blood</i>. 2013;122(17):2943-2964.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/23980065/pubmed\" target=\"_blank\" id=\"23980065\">23980065</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Napolitano LM, Fabian TC, Kelly KM, et al, &quot;Improved Survival of Critically Ill Trauma Patients Treated With Recombinant Human Erythropoietin,&quot; <i>J Trauma</i>, 2008, 65(2):285-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/18695463/pubmed\" target=\"_blank\" id=\"18695463\">18695463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation, &ldquo;KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease,&rdquo; <i>Am J Kidney Dis</i>, 2007, 50(3):529-30.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parissis JT, Kourea K, Panou F, et al, &ldquo;Effects of darbepoetin Alpha on Right and Left Ventricular Systolic and Diastolic Function in Anemic Patients With Chronic Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy,&rdquo; <i>Am Heart J</i>, 2008, 155(4): 751.e1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/18371487/pubmed\" target=\"_blank\" id=\"18371487\">18371487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pfeffer MA, Burdmann EA, Chen CY, et al, &ldquo;A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease,&rdquo; <i>N Engl J Med</i>, 2009, 361(21):2019-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/19880844/pubmed\" target=\"_blank\" id=\"19880844\">19880844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phronmmintikul A, Haas SJ, Elsik M, et al, &ldquo;Mortality and Target Haemoglobin Concentrations in Anaemic Patients with Chronic Kidney Disease Treated With Erythropoietin: A Meta-Analysis,&quot; <i>Lancet</i>, 2007, 369(9559):381-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/17276778/pubmed\" target=\"_blank\" id=\"17276778\">17276778</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qaseem A, Humphrey LL, Fitterman N, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Treatment of anemia in patients with heart disease: a clinical practice guideline from the american college of physicians. <i>Ann Intern Med</i>. 2013;159(11):770-779.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/24297193/pubmed\" target=\"_blank\" id=\"24297193\">24297193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzo JD, Brouwers M, Hurley P, et al, &ldquo;American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer,&rdquo; <i>J Clin Oncol</i>, 2010, 28(33):4996-5010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/20975064/pubmed\" target=\"_blank\" id=\"20975064\">20975064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzo JD, Somerfield MR, Hagerty LK, et al, &ldquo;American Society of Hematology/American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin,&rdquo; <i>Blood</i>, 2008, 111(1):25-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/17954703/pubmed\" target=\"_blank\" id=\"17954703\">17954703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh AJ, Szczech L, Tang Kl, et al, &ldquo;Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease,&rdquo; <i>N Engl J Med</i>, 2006, 355(20):2085-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/17108343/pubmed\" target=\"_blank\" id=\"17108343\">17108343</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16166176\"></a>Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. <i>Ann Oncol</i>. 2005;16(12):1921-1927.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/16166176/pubmed\" target=\"_blank\" id=\"16166176\">16166176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Swedberg K, Young JB, Anand IS, et al; RED-HF Committees; RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. <i>N Engl J Med</i>. 2013;368(13):1210-1219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/23473338/pubmed\" target=\"_blank\" id=\"23473338\">23473338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teehan G and Benz RL, &ldquo;An Update on the Controversies in Anemia Management in Chronic Kidney Disease: Lessons Learned and Lost,&rdquo; <i>Anemia</i>, 2011, 2011:623673.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/21541213/pubmed\" target=\"_blank\" id=\"21541213\">21541213</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Toto RD, Pichette V, Brenner R, et al, &ldquo;Darbepoetin Alfa Effectively Treats Anemia in Patients With Chronic Kidney Disease With de novo Every-Other-Week Administration,&rdquo; <i>Am J Nephrol</i>, 2004, 24(4):453-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/15331889/pubmed\" target=\"_blank\" id=\"15331889\">15331889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vadhan-Raj S, Mirtsching B, Charu V, et al, &ldquo;Assessment of Hematologic Effects and Fatigue in Cancer Patients With Chemotherapy-Induced Anemia Given Darbepoetin Alfa Every Two Weeks,&rdquo; <i>J Support Oncol</i>, 2003, 1(2):131-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/15352656/pubmed\" target=\"_blank\" id=\"15352656\">15352656</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al, &ldquo;Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Two Dosing Regimens of Darbepoetin Alfa in Patients With Heart Failure and Anaemia,&rdquo; <i>Eur Heart J</i>, 2007, 28(18):2208-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/17681958/pubmed\" target=\"_blank\" id=\"17681958\">17681958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Arar MY, Lerner G, et al, &ldquo;Darbepoetin Alfa for the Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease,&rdquo; <i>Pediatr Nephrol</i>, 2006, 21(8):1144-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/16724235/pubmed\" target=\"_blank\" id=\"16724235\">16724235</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8662 Version 163.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50080059\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708695\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F156983\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F156984\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F157010\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F156985\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F5026026\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F156986\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15795977\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15795978\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F156961\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F156947\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874543\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F156963\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F156962\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725530\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2136826\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F156953\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F156966\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F156951\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299127\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F156955\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F156957\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F156969\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20305960\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F156970\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F156959\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F156950\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F156965\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F156968\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038595\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8662|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=darbepoetin-alfa-patient-drug-information\" class=\"drug drug_patient\">Darbepoetin alfa: Patient drug information</a></li><li><a href=\"topic.htm?path=darbepoetin-alfa-pediatric-drug-information\" class=\"drug drug_pediatric\">Darbepoetin alfa: Pediatric drug information</a></li></ul></div></div>","javascript":null}